Lipanthyl

Mentioned in	?		References in periodicals archive	?		Medical browser	?		Full browser	?
fenofibrate	Despite the patent expiry of the two sales-leading coronary heart disease therapies by 2012 -- Sanofi-Aventis/Bristol-Myers Squibb's Plavix/Iscover and Pfizer's Lipitor -- the market entry of fixed-dose combinations with agents such as Abbott's Tricor/TriLipix, Solvay's Lipanthyl and Abbott's Niaspan will also offset the negative impact of generic erosion, according to the report. Despite Patent Expiries of Leading Therapies, New Product Launches ... by BIOTECH Patent News LCP-Feno (containing 145 mg / 48 mg active substance) is being developed as a potential AB-rated, substitutable version of Tricor 145 mg and 48 mg, which is currently marketed in the US by Abbott and in Europe by Solvay under the name Lipanthyl. LifeCycle Pharma: Interim Report For the 9 Months Ended 30 September ... by Business Wire Current Growth Drivers Following the acquisition of Fournier Pharma, Solvay Pharmaceuticals flagship product and principal growth driver is now fenofibrate, a treatment for lipidic disorders which is sold as Tricor in the US and Lipanthyl elsewhere. Research and Markets: Fenofibrate is Solvay Pharmaceuticals Flagship ... by Business Wire	Linstowia lint Linton gag Linum Linum usitatissimum linuron lio- lion Lioresal liothyronine liothyronine sodium liotrix lip Lip Augmentation Lip Lift lip of hip fracture lip reading Lip Reduction lip reflex lip stripping lip(o)- lip- lip-curl lipacidemia lipaciduria Lipanthyl lipase lipase test lipectomy lipedema lipedematous alopecia lipemia lipemia retinalis lipemic Lipeurus lipid lipid granulomatosis lipid histiocytosis lipid hypothesis lipid pneumonia lipid profile lipid proteinosis Lipid Research Clinics Prevalence Study lipid storage diseases lipid-associated sialic acid lipid-soluble vitamins lipidation lipidemia lipidoses lipidosis Lipids	lip-synch lip-synched lip-synched lip-syncher lip-syncher lip-synchers lip-synchers lip-synching lip-synching lip-synchs lip-synchs lip-syncing lip-syncing lip-syncs lip-syncs LIP6 lipa lipa lipa Lipa City lipacidemia lipaciduria lipaemia lipaemia lipaemia Lipalian LIPAM Lipan Lipan Apache Lipans Lipanthyl Lipantil Lipantitlan State Historic Site Lipany Lipari group Lipari group Lipari Islands Lipari Islands Liparian Liparid Liparidae Liparidae Liparididae Liparis Liparis liparis Liparis loeselii Liparite Liparite LIPAS LIPAS LIPAS lipase lipase lipase Lipase Test Lipase-Digested Sesame Oil lipase-Related Proteins 2 Lipases Lipases Lipases Lipatov, Vil

Mentioned in

References in periodicals archive

Medical browser

Full browser

Despite the patent expiry of the two sales-leading coronary heart disease therapies by 2012 -- Sanofi-Aventis/Bristol-Myers Squibb's Plavix/Iscover and Pfizer's Lipitor -- the market entry of fixed-dose combinations with agents such as Abbott's Tricor/TriLipix, Solvay's Lipanthyl and Abbott's Niaspan will also offset the negative impact of generic erosion, according to the report.

Despite Patent Expiries of Leading Therapies, New Product Launches ... by BIOTECH Patent News

LCP-Feno (containing 145 mg / 48 mg active substance) is being developed as a potential AB-rated, substitutable version of Tricor 145 mg and 48 mg, which is currently marketed in the US by Abbott and in Europe by Solvay under the name Lipanthyl.

LifeCycle Pharma: Interim Report For the 9 Months Ended 30 September ... by Business Wire

Current Growth Drivers Following the acquisition of Fournier Pharma, Solvay Pharmaceuticals flagship product and principal growth driver is now fenofibrate, a treatment for lipidic disorders which is sold as Tricor in the US and Lipanthyl elsewhere.

Research and Markets: Fenofibrate is Solvay Pharmaceuticals Flagship ... by Business Wire